trending Market Intelligence /marketintelligence/en/news-insights/trending/kV334D-0KpmXwTg00tqGiA2 content esgSubNav
In This List

CareDx files patent suit against Eurofins Viracor over organ transplant tech

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CareDx files patent suit against Eurofins Viracor over organ transplant tech

CareDx Inc. filed a patent infringement suit against Eurofins Viracor Inc. in the U.S. District Court for Delaware over technology used for organ transplants.

Brisbane, Calif.-based CareDx is asserting U.S. Patent No. 8,703,652 — exclusively licensed to the company from Stanford University — which covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.

CareDx alleges that Eurofins Viracor infringes on the patent by selling a test that performs an analysis of cell-free DNA from patients who have undergone organ transplants to inform on rejection of the organ.

The company said it is pursuing all available remedies, including damages and injunction.